Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed Phenotype in HPV16/18-positive cervical cancer cells

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6495-6503

  Ding, Wencheng ^a   Zhu, Da ^a   Hu, Zheng ^a   Jiang, Xiaohui ^a   Yu, Lan ^a   Wang, Xiaoli ^a   Zhang, Changlin ^a   Wang, Liming ^a   Ji, Teng ^a   Li, Kezhen ^a   He, Dan ^a   Xia, Xi ^b   Liu, Dan ^a   Zhou, Jianfeng ^a   Ma, Ding ^a   Wang, Hui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRUS DNA; ZINC FINGER NUCLEASE; ZINC FINGER NUCLEASE 16 E7 S2; ZINC FINGER NUCLEASE 18 E7 S2; DEOXYRIBONUCLEASE; DNA BINDING PROTEIN; E7 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; ZINC FINGER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DNA CLEAVAGE; DRUG EFFICACY; DRUG SCREENING; EMBRYO; FEMALE; GENE DISRUPTION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE E7; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; VIRUS ONCOGENE; ANIMAL; COMPLICATION; DISEASE MODEL; DNA STRAND BREAKAGE; GENETICS; METABOLISM; PAPILLOMAVIRUS INFECTION; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME; UTERINE CERVICAL NEOPLASMS; VIRUS CELL TRANSFORMATION; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; DISEASE MODELS, ANIMAL; DNA BREAKS; DNA, VIRAL; DNA-BINDING PROTEINS; ENDODEOXYRIBONUCLEASES; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS; ZINC FINGERS;

EID: 84919764923     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0250     Document Type: Article

References (33)

1. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M., Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86.
2. Walboomers JM, Jacobs MV, Manos M.M., Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
3. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10: 550-60.
4. Halbert CL, Demers GW, Galloway DA. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 1991;65:473-8.
5. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 1996;93:2930-5.
6. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A 1996;93:1156-60.
7. Bibikova M, Beumer K, Trautman J.K., Carroll D. Enhancing gene targeting with designed zinc finger nucleases. Science 2003;300:764.
8. Morton J, Davis MW, Jorgensen E.M., Carroll D. Induction and repair of zinc-finger nuclease-targeted double-strand breaks in Caenorhabditis elegans somatic cells. Proc Natl Acad Sci U S A 2006;103:16370-5.
9. Geurts AM, Cost GJ, Freyvert Y, Zeitler B., Miller JC, Choi VM, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science 2009;325:433.
10. Hauschild J, Petersen B, Santiago Y., Queisser AL, Carnwath JW, Lucas-Hahn A, et al. Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases. Proc Natl Acad Sci U S A 2011; 108:12013-7.
11. Perez EE, Wang J, Miller J.C., Jouvenot Y., Kim KA, Liu O, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008;26:808-16.
12. Tebas P, Stein D, Tang W.W., Frank I., Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-10.
13. Tanaka A, Takeda S, Kariya R., Matsuda K, Urano E, Okada S., et al. A novel therapeutic molecule against HTLV-1 infection targeting provirus. Leukemia 2013;27:1621-7.
14. Cradick TJ, Keck K, Bradshaw S., Jamieson AC, McCaffrey AP. Zincfinger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 2010;18:947-54.
15. Doyon Y, Vo TD, Mendel M.C., Greenberg SG, Wang J, Xia DF, et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods 2011;8:74-9.
16. Sander JD, Dahlborg EJ, Goodwin M.J., Cade L., Zhang F, Cifuentes D, et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods 2011;8:67-9.
17. Stanley MA, Browne HM, Appleby M, Minson AC. Properties of a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer 1989;43:672-6.
18. Bechtold V, Beard P, Raj K. Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J Virol 2003;77:2021-8.
19. Bhakta MS, Segal DJ. The generation of zinc finger proteins by modular assembly. Methods Mol Biol 2010;649:3-30.
20. Kim H, Um E, Cho S.R., Jung C., Kim H, Kim JS. Surrogate reporters for enrichment of cells with nuclease-induced mutations. Nat Methods 2011;8:941-3.
21. Workman P, Aboagye EO, Balkwill F, Balmain A., Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
22. Wright DA, Thibodeau-Beganny S, Sander J.D., Winfrey RJ, Hirsh AS, Eichtinger M, et al. Standardized reagents and protocols for engineering zinc finger nucleases by modular assembly. Nat Protoc 2006;1:1637-52.
23. Guo J, Gaj T, Barbas CR. Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol 2010;400:96-107.
24. Miller JC, Holmes MC, Wang J, Guschin D.Y., Lee YL, Rupniewski I, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 2007;25:778-85.
25. Meissner JD. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. J Gen Virol 1999;80:1725-33.
26. Sima N, Wang W, Kong D, Deng D, Xu Q, Zhou J, et al. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis 2008;13:273-81.
27. Jonson AL, Rogers LM, Ramakrishnan S, Downs LJ. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol 2008;111:356-64.
28. Gu W, Putral L, Hengst K., Minto K, Saunders NA, Leggatt G, et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006;13:1023-32.
29. Wu S, Meng L, Wang S., Wang W, Xi L, Tian X., et al. Reversal of the malignant phenotype of cervical cancer CaSki cells through adeno-associated virus-mediated delivery of HPV16 E7 antisense RNA. Clin Cancer Res 2006;12:2032-7.
30. Yamato K, Yamada T, Kizaki M., Ui-Tei K, Natori Y, Fujino M., et al. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther 2008;15:140-53.
31. Rampias T, Sasaki C, Weinberger P., Psyrri A. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009;101:412-23.
32. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009;61:850-62.
33. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;457:426-33.